NCT07286331 2026-03-11
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-Endometrial01)
GlaxoSmithKline
Phase 3 Not yet recruiting
Clinical Trials
20 trialsNCT07463573 2026-03-11
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07441681 2026-03-02
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
NRG Oncology
Phase 3 Not yet recruiting
NCT07416474 2026-02-20
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
RemeGen Co., Ltd.
Phase 3 Not yet recruiting
NCT07419295 2026-02-19
TroFuse-031
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT07418749 2026-02-18
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Not yet recruiting
NCT05411237 2026-01-23
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
AIDS Malignancy Consortium
Phase 3 Not yet recruiting
NCT07360132 2026-01-22
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07286266 2025-12-16
A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
GlaxoSmithKline
Phase 3 Not yet recruiting
NCT06914011 2025-12-03
MRD2START
Asan Medical Center
Phase 3 Not yet recruiting
NCT07262567 2025-12-03
Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT06980545 2025-05-20
Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer
Assiut University
Phase 3 Not yet recruiting
NCT06870565 2025-03-17
Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Not yet recruiting
NCT06867562 2025-03-10
Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer
Jina Pharmaceuticals Inc.
Phase 3 Not yet recruiting
NCT06751485 2024-12-31
JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Not yet recruiting
NCT05990127 2023-08-14
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Akeso
Phase 3 Not yet recruiting
NCT05841381 2023-05-03
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Phase 3 Not yet recruiting
NCT05798819 2023-04-05
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3 Not yet recruiting
NCT05715840 2023-02-08
Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPSâ„1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Not yet recruiting
NCT05388500 2022-05-27
PHARE-C
Institut de cancérologie Strasbourg Europe
Phase 3 Not yet recruiting